We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
(+18%)
Cap. Flow
+$2.78B
Cap. Flow
% of AUM
12.74%
Top 10 Holdings %
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PARA
Paramount Global Class B
PARA
|
+$363M |
| 2 |
Tencent Music
TME
|
+$184M |
| 3 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$182M |
| 4 |
Baidu
BIDU
|
+$146M |
| 5 |
Gaotu Techedu
GOTU
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$204M |
| 2 |
Carnival Corporation Ltd
CCL
|
+$189M |
| 3 |
Zoetis
ZTS
|
+$182M |
| 4 |
Guardant Health
GH
|
+$136M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.15% |
| 3 | Technology | 10.68% |
| 4 | Financials | 9.81% |
| 5 | Communication Services | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bio-Rad Laboratories Class A
BIO
$8.42B
| $325M | 1.49% |
568,918
+199,507
| +54% | +$118M |
|
2
Teleflex
TFX
$5.85B
| $318M | 1.46% |
765,930
-116,989
| -13% | -$46.8M |
|
3
Microsoft
MSFT
$2.84T
| $298M | 1.37% |
1,264,318
+161,250
| +15% | +$37.4M |
|
|
4
Zoetis
ZTS
$31.6B
| $271M | 1.24% |
1,718,375
-1,146,524
| -40% | -$182M |
|
|
PARA
5
DELISTED
Paramount Global Class B
PARA
| $268M | 1.23% |
+5,936,494
| New | +$363M |
|
6
Charles River Laboratories
CRL
$10.9B
| $266M | 1.22% |
917,056
+64,142
| +8% | +$17.8M |
|
7
Amazon
AMZN
$2.5T
| $259M | 1.19% |
1,676,060
+232,920
| +16% | +$36.9M |
|
8
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
| $219M | 1% |
2,511,800
+1,123,500
| +81% | +$97.7M |
|
9
CALL
iShares Russell 2000 ETF
IWM
$80.9B
| $203M | 0.93% |
916,800
+384,800
| +72% | +$84M |
|
|
10
Thermo Fisher Scientific
TMO
$211B
| $201M | 0.92% |
440,115
-427,279
| -49% | -$204M |
|
|
BHVN
11
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $190M | 0.87% |
2,776,467
+219,915
| +9% | +$17.8M |
|
12
Repligen
RGEN
$7.44B
| $183M | 0.84% |
943,724
-537,556
| -36% | -$110M |
|
13
Alibaba
BABA
$269B
| $178M | 0.82% |
784,403
+108,691
| +16% | +$26.7M |
|
14
TransUnion
TRU
$14.8B
| $175M | 0.8% |
1,941,727
-233,051
| -11% | -$21M |
|
|
FTCH
15
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $160M | 0.73% |
3,012,822
+2,976,210
| +8,129% | +$182M |
|
16
Apple
AAPL
$4.89T
| $158M | 0.73% |
1,295,122
+213,652
| +20% | +$27.4M |
|
17
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $157M | 0.72% |
396,800
-547,300
| -58% | -$211M |
|
|
18
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $155M | 0.71% |
703,500
-462,200
| -40% | -$101M |
|
|
19
Tencent Music
TME
$14.5B
| $149M | 0.68% |
+7,253,850
| New | +$184M |
|
|
20
Baidu
BIDU
$35.8B
| $139M | 0.64% |
640,090
+561,039
| +710% | +$146M |
|
|
21
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
| $138M | 0.63% |
1,578,000
-199,900
| -11% | -$17.4M |
|
22
Natera
NTRA
$37.5B
| $119M | 0.55% |
1,174,013
+262,759
| +29% | +$28.8M |
|
|
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
| $115M | 0.53% |
1,752,619
-43,462
| -2% | -$3.05M |
|
24
Intel
INTC
$466B
| $112M | 0.52% |
1,757,170
+1,648,716
| +1,520% | +$98.3M |
|
25
Monster Beverage
MNST
$91.4B
| $111M | 0.51% |
2,444,460
-997,114
| -29% | -$44.7M |
|
Similar funds
Marshall Wace's Q1 2021 Portfolio in Review
As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.
- Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
- Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
- Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
- Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
- Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
- Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
- Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.
Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.